Table 3.
Univariate and multivariate Cox proportional hazards models of the effect of variables on the PTLD time of onset.
| SOT—Univariate | KTR—Univariate | LTR—Univariate | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | p-Value | Variable | HR | 95% CI | p-Value | Variable | HR | 95% CI | p-Value |
| Male sex | 1.49 | (0.74–3.02) | 0.269 | Male sex | 4.86 | (1.03–22.81) | 0.045 * | Male sex | 1.03 | (0.44–2.44) | 0.939 |
| Age at Tx > 45 years | 1.03 | (1.01–1.05) | 0.006 * | Age at Tx > 45 years | 1.04 | (1.00–1.07) | 0.044 * | Age at Tx > 45 years | 1.02 | (0.98–1.05) | 0.357 |
| Retransplantation | 0.96 | (0.29–3.2) | 0.95 | Retransplantation | 2.46 | (0.29–21.12) | 0.412 | Retransplantation | 0.46 | (0.1–2.04) | 0.306 |
| Monotherapy | 2.18 | (0.81–5.84) | 0.12 | Monotherapy | NA | NA | NA | Monotherapy | 1.11 | (0.41–3.06) | 0.835 |
| Double drug therapy | 0.88 | (0.46–1.67) | 0.69 | Double drug therapy | 0.56 | (0.19–1.61) | 0.282 | Double drug therapy | 1.18 | (0.51–2.75) | 0.695 |
| Triple drug therapy | 0.97 | (0.51–1.86) | 0.934 | Triple drug therapy | 1.79 | (0.62–5.14) | 0.282 | Triple drug therapy | 0.91 | (0.35–2.36) | 0.851 |
| GCS | 0.87 | (0.43–1.78) | 0.703 | GCS | 0.68 | (0.18–2.59) | 0.574 | GCS | 1.66 | (0.7–3.94) | 0.247 |
| CsA | 0.44 | (0.20–0.95) | 0.036 * | CsA | 0.59 | (0.21–1.64) | 0.31 | CsA | 4.55 | (0.91–22.8) | 0.065 |
| TAC | 5.09 | (2.00–12.95) | <0.001 * | TAC | 6.25 | (1.68–23.21) | 0.006 * | TAC | 0.22 | (0.04–1.1) | 0.065 |
| AZA | 0.68 | (0.28–1.64) | 0.385 | AZA | 1.28 | (0.42–3.95) | 0.664 | AZA | 0.58 | (0.08–4.39) | 0.596 |
| MMF | 0.78 | (0.41–1.5) | 0.463 | MMF | 1.04 | (0.36–3.05) | 0.936 | MMF | 0.68 | (0.28–1.64) | 0.399 |
| ATG induction | 0.33 | (0.04–2.52) | 0.288 | ATG induction | 0.48 | (0.06–3.8) | 0.488 | ATG induction | NA | NA | NA |
| Anti-CD25 induction | 1.35 | (0.69–2.64) | 0.376 | Anti-CD25 induction | 0.74 | (0.2–2.67) | 0.645 | Anti-CD25 induction | 1.07 | (0.44–2.6) | 0.884 |
| AR treated with GCS | 0.75 | (0.37–1.51) | 0.413 | AR treated with GCS | 0.61 | (0.18–2.01) | 0.413 | AR treated with GCS | 0.72 | (0.3–1.76) | 0.476 |
| AR treated with ATG | 1.38 | (0.18–10.37) | 0.753 | AR treated with ATG | NA | NA | NA | AR treated with ATG | 0.9 | (0.12–6.93) | 0.922 |
| EBV DNA | 0.72 | (0.31–1.68) | 0.447 | EBV DNA | 0.7 | (0.08–6.03) | 0.744 | EBV DNA | 1.66 | (0.62–4.43) | 0.314 |
| CMV DNA | 0.6 | (0.14–2.51) | 0.482 | CMV DNA | 1.26 | (0.27–5.87) | 0.767 | CMV DNA | NA | NA | NA |
| HBV DNA | 0.86 | (0.26–2.83) | 0.802 | HBV DNA | 0.61 | (0.08–4.78) | 0.638 | HBV DNA | 1.32 | (0.3–5.85) | 0.718 |
| HCV RNA | 1.08 | (0.45–2.61) | 0.861 | HCV RNA | 0.48 | (0.06–3.8) | 0.488 | HCV RNA | 0.96 | (0.35–2.65) | 0.942 |
| SOT—Multivariate | KTR—Multivariate | LTR—Multivariate | |||||||||
| Variable | HR | 95% CI | p-Value | Variable | HR | 95% CI | p-Value | Variable | HR | 95% CI | p-Value |
| LTx | 1.75 | (0.63–4.83) | 0.281 | Male sex | 7.87 | (1.25–49.26) | 0.027 * | Male sex | 0.872 | (0.36–2.13) | 0.746 |
| Age at Tx > 45 years | 3.16 | (1.4–7.1) | 0.005 * | Age at Tx > 45 years | 5.21 | (1.04–26.25) | 0.045 * | Age at Tx > 45 years | 1.61 | (0.62–4.21) | 0.332 |
| TAC | 5.85 | (0.89–38.24) | 0.065 | TAC | 18.57 | (2.79–123.87) | 0.003 * | TAC | 0.24 | (0.04–1.35) | 0.107 |
| CsA | 1.91 | (0.39–9.31) | 0.423 |
AR—acute rejection, ATG—anti-thymocyte globulin, AZA—azathioprine, CMV—cytomegalovirus, CsA—cyclosporin, EBV—Epstein-Barr virus, GCs—glucocorticosteroids, HBV—hepatitis B virus, HCV—Hepatitis C virus, KT+LTRs—non-simultaneous kidney and liver transplant recipients, KTRs—kidney transplant recipients, LTRs—liver transplant recipients, LTx—liver transplantation, MMF—mycophenolate mofetil, SOT—solid organ transplantation group, TAC—tacrolimus, Tx—transplantation. Wald test’s p-values. * p < 0.05, NA—not applicable.